Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 44.50p 42.00p 47.00p 44.50p 43.50p 43.50p 2,326 08:00:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 14.3 -1.1 -3.8 - 16.39

Venture Life Share Discussion Threads

Showing 17301 to 17324 of 17325 messages
Chat Pages: 693  692  691  690  689  688  687  686  685  684  683  682  Older
DateSubjectAuthorDiscuss
23/2/2018
14:36
Great blog by Paton on TSTL hxxps://maynardpaton.com/2018/02/23/tristel-h1-results-boast-24-profit-jump-before-north-american-costs-as-epa-decision-now-set-for-16-april/
glaws2
23/2/2018
12:10
Think that's the key to the worth of the vlg thread. Very human and humble. Shared experience and knowledge equals greater results for all. Commiserations when someone gets it wrong and congratulations when someone gets it right.
thelongandtheshortandthetall
23/2/2018
11:31
Morning Janeann, very honest to admit to being human. So many posters if they are to be believed get it right every time and trade every movement and try to encourage others to copy, I tend not to believe a word.
melton john
23/2/2018
10:14
Is jerry looking at the same balance sheet as me? hxxp://www.proactive investors.co.uk/companies/stocktube/8793/venture-life-has-sights-set-on-expanding-presence-in-us-market-8793.html I do wish advfn would stop this silly juvenile attitude towards posting links to other financial websites woody
woodcutter
23/2/2018
08:30
when dips get too deep I get scared and cant bring myself to add. thinking there must be something driving it down. the mistake is then buying when it gets back to the top. (unless its prsm of course!)
janeann
23/2/2018
08:08
Significantly higher than the early Feb. BTFD opportunity, j. apad😎
apad
23/2/2018
07:57
thanks on 2 counts apad; second plus the info on mcgn - although that was a few days ago. it has dipped a long way back - disappointing really
janeann
23/2/2018
07:47
"We are fully committed to helping insurers manage the incredible complexities of IFRS 17. This is a billion-dollar problem that must be tackled by an industry already under significant pressures. With almost 40% of insurers expected to kick off their implementation projects in Q2 2018, we advise that insurers act now and avoid a potential skills shortage in the market. Potentially, then, a huge growth market for Microgen over the next few years."
apad
23/2/2018
07:44
hxxp://www.theregister.co.uk/2018/02/22/lloyds_to_splash_3bn_on_tech/
apad
23/2/2018
07:01
The Comparison average is -2.2%. At least it is outperforming the all-share at -5.4%. Stars are -5% and Stalwarts -1.5% janeann is a very creditable +9% and high risk Mattjos is down to +20% :-) Stairway is +3.4% (apad😊 is well pleased) End of month, next week. apad😎
apad
23/2/2018
06:53
IC this morning. Phew! Buy on KWS - talk about missing the boat! Buy on LTG - joining the bandwagon. Buy on TSTL 'cos of April in yoodleland - that's gonna be a popular tintin theme 😊 Buy on LLOY - pretty obvious now. Buy on AZN - nothing new there then! Good article by Bearbull comparing SPX and RSW - this Bearbull is doin' proper research (unlike the last one). Another set of tintins analysing a 'reader's' portfolio. As usual the financial approach to spreading risk is based on zero analysis of the businesses and entirely on balance sheets. The contrast between my approach, that is based on the desirability of the business first (and not selling whilst the story is extant), which has produced an unbalanced portfolio that would give tintins apoplexy is remarkable. I must stay scared. Here is the degree of my imbalance: FEVR BOO ABC RSW BVXP TSTL DOTD AMS SPX PRV HLMA PTSG FARN QTX FFX VCT SOU NTQ ZOO DPH IDEA ARC 26.3% 15.2% 12.3% 7.7% 6.4% 4.9% 3.5% 3.5% 3.5% 3.4% 3.2% 2.8% 2.4% 1.2% 1.1% 0.9% 0.8% 0.4% 0.2% 0.1% 0.1% 0.08% apad😎
apad
22/2/2018
11:17
Ploughed my way through the FARN R&D day presentation - now "confused, but at a much higher level". Here are my notes: ARDS is caused by a common mechanism (epithelial penetration) - not just associated with pneumonia. Other organs have the same capillary problems that the lungs have - just more capillaries in the lungs. The problem is associated with trauma and surgery, as well as disease. Faron is intending to look at Traumakine in other areas, after expected commercial rollout in 2019 becaue their drug addresses the universal body mechanism. Going alone or with a partner compared with licensing gives 80% cash retention compared with 20%. Ten year exclusivity, Clevegen is also based on their fundamental technology - blocking penetration into capillaries. Applied to pancreatic, ovarian and liver cancer for example. Combined Phase I/II trial. apad😎
apad
22/2/2018
09:47
Morgan Sindall year-end results as expected How could anyone have doubted .... except mr. market
piedro
22/2/2018
09:42
ARC - the reduction in cash from operations appears to be working cap related. Large increase in receivables partially offset by less large increase in payables. Not sure about "new" customers. The trialist converted to customer of the new desktop product is almost certainly one of the large existing customers so not "new" to the group. Not sure about the new client for the cache and calculations engine.
gsbmba99
22/2/2018
09:14
ps ARC Time Price Qty Type Bid Offer B/S Total Buy Total Sell 08:59:58 61.0000 3,142 O 61.0000 65.0000 Sell 0 6,142 08:49:03 63.0000 3,000 O 63.0000 65.0000 Sell 0 3,000
apad
22/2/2018
09:10
ARC. New customer reported in two product descriptions - probably the same one. No comment on the huge drop in net cash generated from operating activities. So, presumably for some reason I haven't been able to define from a quick first glance. apad🤔
apad
22/2/2018
07:16
very simple and acceptable update from arc; & plenty of cash in the bank.; Highlights: -- Turnover increased by 9% to GBP1,213,776 (six months ended 31 December 2016: GBP1,115,232) -- Profit before tax increased by 10% to GBP237,581 (six months ended 31 December 2016: GBP216,270) -- Annual run-rate of recurring revenues at 31 December 2017 increased by 13% to GBP2.43 million (at 31 December 2016: GBP2.15 million). Net cash of GBP2,663,935 as at 31 December 2017 (31 December 2016: GBP2,089,855) -- Trading in line and on track to meet management's full year expectations Richard Last, Chairman of Arcontech Group, said: "Arcontech's ongoing investment in product development and enhancement, coupled with the flexibility provided by its strong balance sheet and high level of recurring revenues, supports the Board's confidence in the Groups long term future and its ability to meet the challenges in its business environment. Although we remain mindful of the long and unpredictable sales cycles we often face and the challenges this brings in predicting the timing of contract wins, the Board expects results for the full year to be in line with expectations."
janeann
21/2/2018
19:06
I bought in here some time ago on the basis that the business looked a good prospect and the spike down on the chart brought some reality back to the share price I ultimately sold around break even taking the decision to look again when the share price settled, in the main because of the financial position. Well I'm not sure if it's settled though a double bottom is a good sign. The real issue for me is very similar to investors champion and my reason for selling remains. The growth in sales and EBITDA looks great but the balance sheet is very weak and it's generating no cash to support the working capital requirements. They could do with trying to reduce the receivables. The fact they did a presentation to potential bond holders in November tells you all you need to know.................they are running out of cash and will need to do a placing at some point imo. There's a lot of loan note debt. Maybe the directors don't wish to be diluted and can't afford to have a share placing but that's needed imho I may be wrong and the next results will give us a better impression of the cash position but @ H1 with only £1.3m of cash on the balance sheet and nearly £8m of costs to come in the second half (granted some of that will be trade creditors) it looks stretched to me. Looks to be a lot of money tied up in working capital too. woody
woodcutter
21/2/2018
14:06
Hes creaming 0.5% off a huge wad of AuM. Why does he need to pick good stocks? The outflows at the moment must be hurting tho.
mozy123
21/2/2018
13:10
Woodford has lost it.
11_percent
21/2/2018
12:31
Yes another disaster. His reputation is now visibly damaged - I've noticed the slow to react press talking about his recent below par performance (sometimes whilst still referring to him as 'star fund manager')
hydrus
21/2/2018
11:48
Odds Bodikins, AA is another major Woodford stock. apad🤔
apad
21/2/2018
09:30
"Samsung has provided confirmation that iPhone X sales are way below Apple's estimates for the much-hyped, tenth anniversary special."
apad
21/2/2018
09:27
As a partner organisation since 2007 my thinking was that FFX should be well placed to know about IT/comms compatibility issues. It's a good marker to have though - be worth looking out for exceptional IT costs further down the line.
rp19
Chat Pages: 693  692  691  690  689  688  687  686  685  684  683  682  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180223 14:57:26